semaglutide risks The obesity drug (Wegovy) conferred a significantly higher risk of ischemic optic neuropathy (ION) than any other GLP-1 agonist, including semaglutide for diabetes (Ozempic), an analysis of FDA data showed. Added Semaglutide cardiovascular outcomes align more

Hepatic GCGR activation stimulates gluconeogenesis while simultaneously reducing hepatic fat content through inhibition of de novo lipogenesis and promotion of mitochondrial fatty acid oxidation

You can customize any therapy to fit your wellness goals

We identified downregulation of mitochondrial programs in multiple non-proximal tubular cell populations compared with their counterparts in healthy kidneys

If your primary concern is pigmentation, glutathione is clearly the more effective option

Cardiovascular and Metabolic Benefits : Semaglutide, as demonstrated in the SELECT trial, has established long-term cardiovascular benefits, with an average weight loss of 10.2% over four years, highlighting its role in cardiometabolic risk reduction